schliessen

Filtern

 

Bibliotheken

Oestrogen receptor-negative/progesterone receptor-positive phenotype of invasive breast carcinoma in Japan: re-evaluated using immunohistochemical staining

Background The existence of progesterone receptor (PgR) expression in oestrogen receptor (ER)-negative breast carcinoma is controversial. Here, we re-evaluated ER-negative/PgR-positive (ER−/PgR+) carcinoma cases by immunohistochemical staining (IHC). Materials and methods We selected patients who un... Full description

Journal Title: Breast Cancer (Tokyo Japan), 2018-07-31, Vol.26 (2), p.249-254
Main Author: Kuroda, Hajime
Other Authors: Muroi, Nozomi , Hayashi, Mitsuhiro , Harada, Oi , Hoshi, Kazuei , Fukuma, Eisuke , Abe, Akihito , Kubota, Keiichi , Imai, Yasuo
Format: Electronic Article Electronic Article
Language: English
Subjects:
Re
Publisher: Tokyo: Springer Japan
ID: ISSN: 1340-6868
Link: https://www.ncbi.nlm.nih.gov/pubmed/30066060
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6394606
title: Oestrogen receptor-negative/progesterone receptor-positive phenotype of invasive breast carcinoma in Japan: re-evaluated using immunohistochemical staining
format: Article
creator:
  • Kuroda, Hajime
  • Muroi, Nozomi
  • Hayashi, Mitsuhiro
  • Harada, Oi
  • Hoshi, Kazuei
  • Fukuma, Eisuke
  • Abe, Akihito
  • Kubota, Keiichi
  • Imai, Yasuo
subjects:
  • Breast cancer
  • Breast carcinoma
  • Cancer
  • Cancer Research
  • Carcinoma
  • connective tissue diseases
  • endocrine system
  • Estrogen
  • evaluation
  • Genetic aspects
  • hormone antagonists
  • hormone substitutes
  • hormones
  • Immunohistochemical staining
  • Immunohistochemistry
  • Medical colleges
  • Medicine
  • Medicine & Public Health
  • Oestrogen receptor
  • Oncology
  • Progesterone
  • Progesterone receptor
  • Rapid Communication
  • Re
  • Re-evaluation
  • skin
  • Surgery
  • Surgical Oncology
ispartof: Breast Cancer (Tokyo, Japan), 2018-07-31, Vol.26 (2), p.249-254
description: Background The existence of progesterone receptor (PgR) expression in oestrogen receptor (ER)-negative breast carcinoma is controversial. Here, we re-evaluated ER-negative/PgR-positive (ER−/PgR+) carcinoma cases by immunohistochemical staining (IHC). Materials and methods We selected patients who underwent surgery for primary breast carcinoma from our databases at Dokkyo Medical University Hospital and Kameda General Hospital. Among the 9844 patients, the largest series in Japan, 27 (0.3%) were initially diagnosed as ER−/PgR+ breast carcinomas and we re-evaluated by IHC. Results The re-evaluated IHC showed that of the 27 patients with the initial results of ER−/PgR+, 12 were ER+/PgR+, 8 were ER−/PgR−, and 7 were ER−/PgR+. ER was negative in 12 of 27 patients (44.4%), and PgR was positive in 8 of 27 patients (29.6%). In our seven re-evaluated and confirmed as ER−/PgR+ cases, the staining proportions of tumor cells were 0% in ER and 1–69% (average 15.8%) in PgR. The average staining proportion of PgR in the re-evaluated ER−/PgR+ phenotype was lower than the initial diagnosis. Histological grading was as follows: grade I, one case; grade II, two cases; grade III, four cases. There were two lymph-node-positive cases. Conclusions The ER−/PgR+ phenotype was confirmed after re-evaluation of ER and PgR assessment by a different pathologist. We recommend that pathologists discuss with clinicians, or re-test and re-evaluate ER/PgR expression, particularly in low-grade carcinoma and with a high staining proportion of PgR in the ER−/PgR+ phenotype.
language: eng
source:
identifier: ISSN: 1340-6868
fulltext: no_fulltext
issn:
  • 1340-6868
  • 1880-4233
url: Link


@attributes
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
RANK2.4579651
LOCALfalse
PrimoNMBib
record
control
sourceidgale_pubme
recordidTN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6394606
sourceformatXML
sourcesystemPC
galeidA575911788
sourcerecordidA575911788
originalsourceidFETCH-LOGICAL-1555t-116298c2d210fd5e05b063ab9dd532280e1fdc7fc229d29829d2cb683f2c71730
addsrcrecordideNp9Uk2L1TAULaI449Mf4EYKbtx0Jh-vaepCGAZ1lIHZ6DrcJrd9GdqkJumD-S3-WVM6jg6IBJKQc-7JzckpiteUnFFCmvNIGZOsIlRWRLayap8Up1RKUu0Z50_znu9JJaSQJ8WLGG8J2fOGiOfFCSdECCLIafHzBmMKfkBXBtQ4Jx8qhwMke8TzeQViwuAd_oFnH-0Kl_MBnU93M5a-L607QlxPu4AQU6khaOv8BBkpv8IM7n2WqPAI4wIJTblE64bSTtPi_MHG5PUBJ6thLGMC6zL4snjWwxjx1f26K75_-vjt8qq6vvn85fLiuqJ1XaeKUsFaqZlhlPSmRlJ3RHDoWmNqng0iSHujm14z1prMXGfdCcl7phvacLIrPmy689JNaDS6FGBUc7AThDvlwarHiLMHNfijErzdrzbuiqtNwM_owAZ8VGscJuWNYqJRUpg973paEyZlY4Ay0nW9ASaBQct1lnp330vwP5Zsvpps1DiO4NAvUTEi11fnmzP17UYdYERlXe9zc3qlq4u6qVtKm5yFXXH2D1YeZnU7f2xv8_mjAroV6OBjDNg_PIYStcZObbFTOXZqjZ1aW3nzt4MPFb9zlglsI8QMuQGDuvVLcPlX_6P6C2vG5iE
sourcetypeOpen Access Repository
isCDItrue
recordtypearticle
pqid2081555639
display
typearticle
titleOestrogen receptor-negative/progesterone receptor-positive phenotype of invasive breast carcinoma in Japan: re-evaluated using immunohistochemical staining
creatorKuroda, Hajime ; Muroi, Nozomi ; Hayashi, Mitsuhiro ; Harada, Oi ; Hoshi, Kazuei ; Fukuma, Eisuke ; Abe, Akihito ; Kubota, Keiichi ; Imai, Yasuo
creatorcontribKuroda, Hajime ; Muroi, Nozomi ; Hayashi, Mitsuhiro ; Harada, Oi ; Hoshi, Kazuei ; Fukuma, Eisuke ; Abe, Akihito ; Kubota, Keiichi ; Imai, Yasuo
descriptionBackground The existence of progesterone receptor (PgR) expression in oestrogen receptor (ER)-negative breast carcinoma is controversial. Here, we re-evaluated ER-negative/PgR-positive (ER−/PgR+) carcinoma cases by immunohistochemical staining (IHC). Materials and methods We selected patients who underwent surgery for primary breast carcinoma from our databases at Dokkyo Medical University Hospital and Kameda General Hospital. Among the 9844 patients, the largest series in Japan, 27 (0.3%) were initially diagnosed as ER−/PgR+ breast carcinomas and we re-evaluated by IHC. Results The re-evaluated IHC showed that of the 27 patients with the initial results of ER−/PgR+, 12 were ER+/PgR+, 8 were ER−/PgR−, and 7 were ER−/PgR+. ER was negative in 12 of 27 patients (44.4%), and PgR was positive in 8 of 27 patients (29.6%). In our seven re-evaluated and confirmed as ER−/PgR+ cases, the staining proportions of tumor cells were 0% in ER and 1–69% (average 15.8%) in PgR. The average staining proportion of PgR in the re-evaluated ER−/PgR+ phenotype was lower than the initial diagnosis. Histological grading was as follows: grade I, one case; grade II, two cases; grade III, four cases. There were two lymph-node-positive cases. Conclusions The ER−/PgR+ phenotype was confirmed after re-evaluation of ER and PgR assessment by a different pathologist. We recommend that pathologists discuss with clinicians, or re-test and re-evaluate ER/PgR expression, particularly in low-grade carcinoma and with a high staining proportion of PgR in the ER−/PgR+ phenotype.
identifier
0ISSN: 1340-6868
1EISSN: 1880-4233
2DOI: 10.1007/s12282-018-0898-9
3PMID: 30066060
languageeng
publisherTokyo: Springer Japan
subjectBreast cancer ; Breast carcinoma ; Cancer ; Cancer Research ; Carcinoma ; connective tissue diseases ; endocrine system ; Estrogen ; evaluation ; Genetic aspects ; hormone antagonists ; hormone substitutes ; hormones ; Immunohistochemical staining ; Immunohistochemistry ; Medical colleges ; Medicine ; Medicine & Public Health ; Oestrogen receptor ; Oncology ; Progesterone ; Progesterone receptor ; Rapid Communication ; Re ; Re-evaluation ; skin ; Surgery ; Surgical Oncology
ispartofBreast Cancer (Tokyo, Japan), 2018-07-31, Vol.26 (2), p.249-254
rights
0The Author(s) 2018
1COPYRIGHT 2019 Springer
lds50peer_reviewed
oafree_for_read
citesFETCH-LOGICAL-1555t-116298c2d210fd5e05b063ab9dd532280e1fdc7fc229d29829d2cb683f2c71730
links
openurl$$Topenurl_article
thumbnail$$Usyndetics_thumb_exl
backlink$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30066060$$D View this record in MEDLINE/PubMed
search
creatorcontrib
0Kuroda, Hajime
1Muroi, Nozomi
2Hayashi, Mitsuhiro
3Harada, Oi
4Hoshi, Kazuei
5Fukuma, Eisuke
6Abe, Akihito
7Kubota, Keiichi
8Imai, Yasuo
title
0Oestrogen receptor-negative/progesterone receptor-positive phenotype of invasive breast carcinoma in Japan: re-evaluated using immunohistochemical staining
1Breast Cancer (Tokyo, Japan)
addtitle
0Breast Cancer
1Breast Cancer
descriptionBackground The existence of progesterone receptor (PgR) expression in oestrogen receptor (ER)-negative breast carcinoma is controversial. Here, we re-evaluated ER-negative/PgR-positive (ER−/PgR+) carcinoma cases by immunohistochemical staining (IHC). Materials and methods We selected patients who underwent surgery for primary breast carcinoma from our databases at Dokkyo Medical University Hospital and Kameda General Hospital. Among the 9844 patients, the largest series in Japan, 27 (0.3%) were initially diagnosed as ER−/PgR+ breast carcinomas and we re-evaluated by IHC. Results The re-evaluated IHC showed that of the 27 patients with the initial results of ER−/PgR+, 12 were ER+/PgR+, 8 were ER−/PgR−, and 7 were ER−/PgR+. ER was negative in 12 of 27 patients (44.4%), and PgR was positive in 8 of 27 patients (29.6%). In our seven re-evaluated and confirmed as ER−/PgR+ cases, the staining proportions of tumor cells were 0% in ER and 1–69% (average 15.8%) in PgR. The average staining proportion of PgR in the re-evaluated ER−/PgR+ phenotype was lower than the initial diagnosis. Histological grading was as follows: grade I, one case; grade II, two cases; grade III, four cases. There were two lymph-node-positive cases. Conclusions The ER−/PgR+ phenotype was confirmed after re-evaluation of ER and PgR assessment by a different pathologist. We recommend that pathologists discuss with clinicians, or re-test and re-evaluate ER/PgR expression, particularly in low-grade carcinoma and with a high staining proportion of PgR in the ER−/PgR+ phenotype.
subject
0Breast cancer
1Breast carcinoma
2Cancer
3Cancer Research
4Carcinoma
5connective tissue diseases
6endocrine system
7Estrogen
8evaluation
9Genetic aspects
10hormone antagonists
11hormone substitutes
12hormones
13Immunohistochemical staining
14Immunohistochemistry
15Medical colleges
16Medicine
17Medicine & Public Health
18Oestrogen receptor
19Oncology
20Progesterone
21Progesterone receptor
22Rapid Communication
23Re
24Re-evaluation
25skin
26Surgery
27Surgical Oncology
issn
01340-6868
11880-4233
fulltextfalse
rsrctypearticle
creationdate2018
recordtypearticle
recordideNp9Uk2L1TAULaI449Mf4EYKbtx0Jh-vaepCGAZ1lIHZ6DrcJrd9GdqkJumD-S3-WVM6jg6IBJKQc-7JzckpiteUnFFCmvNIGZOsIlRWRLayap8Up1RKUu0Z50_znu9JJaSQJ8WLGG8J2fOGiOfFCSdECCLIafHzBmMKfkBXBtQ4Jx8qhwMke8TzeQViwuAd_oFnH-0Kl_MBnU93M5a-L607QlxPu4AQU6khaOv8BBkpv8IM7n2WqPAI4wIJTblE64bSTtPi_MHG5PUBJ6thLGMC6zL4snjWwxjx1f26K75_-vjt8qq6vvn85fLiuqJ1XaeKUsFaqZlhlPSmRlJ3RHDoWmNqng0iSHujm14z1prMXGfdCcl7phvacLIrPmy689JNaDS6FGBUc7AThDvlwarHiLMHNfijErzdrzbuiqtNwM_owAZ8VGscJuWNYqJRUpg973paEyZlY4Ay0nW9ASaBQct1lnp330vwP5Zsvpps1DiO4NAvUTEi11fnmzP17UYdYERlXe9zc3qlq4u6qVtKm5yFXXH2D1YeZnU7f2xv8_mjAroV6OBjDNg_PIYStcZObbFTOXZqjZ1aW3nzt4MPFb9zlglsI8QMuQGDuvVLcPlX_6P6C2vG5iE
startdate20180731
enddate20180731
creator
0Kuroda, Hajime
1Muroi, Nozomi
2Hayashi, Mitsuhiro
3Harada, Oi
4Hoshi, Kazuei
5Fukuma, Eisuke
6Abe, Akihito
7Kubota, Keiichi
8Imai, Yasuo
general
0Springer Japan
1Springer
scope
0NPM
1AAYXX
2CITATION
3BSHEE
47X8
5BOBZL
6CLFQK
75PM
sort
creationdate20180731
titleOestrogen receptor-negative/progesterone receptor-positive phenotype of invasive breast carcinoma in Japan: re-evaluated using immunohistochemical staining
authorKuroda, Hajime ; Muroi, Nozomi ; Hayashi, Mitsuhiro ; Harada, Oi ; Hoshi, Kazuei ; Fukuma, Eisuke ; Abe, Akihito ; Kubota, Keiichi ; Imai, Yasuo
facets
frbrtype5
frbrgroupidcdi_FETCH-LOGICAL-1555t-116298c2d210fd5e05b063ab9dd532280e1fdc7fc229d29829d2cb683f2c71730
rsrctypearticles
prefilterarticles
languageeng
creationdate2018
topic
0Breast cancer
1Breast carcinoma
2Cancer
3Cancer Research
4Carcinoma
5connective tissue diseases
6endocrine system
7Estrogen
8evaluation
9Genetic aspects
10hormone antagonists
11hormone substitutes
12hormones
13Immunohistochemical staining
14Immunohistochemistry
15Medical colleges
16Medicine
17Medicine & Public Health
18Oestrogen receptor
19Oncology
20Progesterone
21Progesterone receptor
22Rapid Communication
23Re
24Re-evaluation
25skin
26Surgery
27Surgical Oncology
toplevelpeer_reviewed
creatorcontrib
0Kuroda, Hajime
1Muroi, Nozomi
2Hayashi, Mitsuhiro
3Harada, Oi
4Hoshi, Kazuei
5Fukuma, Eisuke
6Abe, Akihito
7Kubota, Keiichi
8Imai, Yasuo
collection
0PubMed
1CrossRef
2Academic OneFile (A&I only)
3MEDLINE - Academic
4OpenAIRE (Open Access)
5OpenAIRE
6PubMed Central (Full Participant titles)
jtitleBreast Cancer (Tokyo, Japan)
delivery
delcategoryRemote Search Resource
fulltextno_fulltext
addata
au
0Kuroda, Hajime
1Muroi, Nozomi
2Hayashi, Mitsuhiro
3Harada, Oi
4Hoshi, Kazuei
5Fukuma, Eisuke
6Abe, Akihito
7Kubota, Keiichi
8Imai, Yasuo
formatjournal
genrearticle
ristypeJOUR
atitleOestrogen receptor-negative/progesterone receptor-positive phenotype of invasive breast carcinoma in Japan: re-evaluated using immunohistochemical staining
jtitleBreast Cancer (Tokyo, Japan)
stitleBreast Cancer
addtitleBreast Cancer
date2018-07-31
risdate2018
volume26
issue2
spage249
epage254
pages249-254
issn1340-6868
eissn1880-4233
abstractBackground The existence of progesterone receptor (PgR) expression in oestrogen receptor (ER)-negative breast carcinoma is controversial. Here, we re-evaluated ER-negative/PgR-positive (ER−/PgR+) carcinoma cases by immunohistochemical staining (IHC). Materials and methods We selected patients who underwent surgery for primary breast carcinoma from our databases at Dokkyo Medical University Hospital and Kameda General Hospital. Among the 9844 patients, the largest series in Japan, 27 (0.3%) were initially diagnosed as ER−/PgR+ breast carcinomas and we re-evaluated by IHC. Results The re-evaluated IHC showed that of the 27 patients with the initial results of ER−/PgR+, 12 were ER+/PgR+, 8 were ER−/PgR−, and 7 were ER−/PgR+. ER was negative in 12 of 27 patients (44.4%), and PgR was positive in 8 of 27 patients (29.6%). In our seven re-evaluated and confirmed as ER−/PgR+ cases, the staining proportions of tumor cells were 0% in ER and 1–69% (average 15.8%) in PgR. The average staining proportion of PgR in the re-evaluated ER−/PgR+ phenotype was lower than the initial diagnosis. Histological grading was as follows: grade I, one case; grade II, two cases; grade III, four cases. There were two lymph-node-positive cases. Conclusions The ER−/PgR+ phenotype was confirmed after re-evaluation of ER and PgR assessment by a different pathologist. We recommend that pathologists discuss with clinicians, or re-test and re-evaluate ER/PgR expression, particularly in low-grade carcinoma and with a high staining proportion of PgR in the ER−/PgR+ phenotype.
copTokyo
pubSpringer Japan
pmid30066060
doi10.1007/s12282-018-0898-9
oafree_for_read